Novo Nordisk invests DKK 1.5 billion in new haemophilia treatment manufacturing facility in Denmark

Novo Nordisk invests DKK 1.5 billion in new haemophilia treatment manufacturing facility in Denmark

Bagsværd, Denmark, 4 May 2015 - Novo Nordisk is investing 1.5 billion Danish kroner in a new 7,500 m2 facility in Kalundborg, Denmark. The facility will produce active pharmaceutical ingredients for NovoSeven® and future products for treating haemophilia. 

The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people.

"The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees," said Henrik Wulff, executive vice president, Product Supply, Novo Nordisk.

Groundbreaking will take place today, 4 May, and the facility is expected to be approved and fully operational in 2020.

About Novo Nordisk in Kalundborg

Established in 1969, the Kalundborg production site is Novo Nordisk's largest with a total area of 1,000,000 m2. Novo Nordisk has made ongoing investments in the site since 1999, creating more than 1,600 new jobs.

About haemophilia

Haemophilia is a bleeding disorder affecting 1 in 10,000 people. People with haemophilia have either decreased, defective or absent production of blood clotting protein. For people with haemophilia, bleeds often occur in the joints, particularly knees and ankles. Bleeds can also occur in the muscles, soft tissues, gastrointestinal tract or even the brain. Without adequate care and treatment, bleeds are painful and can cause lasting damage and lead to impaired mobility. Novo Nordisk is committed to Changing Possibilities in Haemophilia® working towards a future where all people living with haemophilia have the opportunity to lead the life they desire.

Further information

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.